Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4862098
Max Phase: Preclinical
Molecular Formula: C56H75F15N14O17
Molecular Weight: 931.16
Molecule Type: Unknown
Associated Items:
ID: ALA4862098
Max Phase: Preclinical
Molecular Formula: C56H75F15N14O17
Molecular Weight: 931.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NCCN1CCN(CCC(=O)NC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C46H70N14O7.5C2HF3O2/c1-31(42(64)56-37(12-7-8-19-47)45(67)53-32(2)61)52-44(66)36(13-9-20-51-46(48)49)50-21-25-58-28-26-57(27-29-58)24-18-40(62)54-33-16-22-59(23-17-33)30-41(63)60-38-14-5-3-10-34(38)43(65)55-35-11-4-6-15-39(35)60;5*3-2(4,5)1(6)7/h3-6,10-11,14-15,31,33,36-37,50H,7-9,12-13,16-30,47H2,1-2H3,(H,52,66)(H,54,62)(H,55,65)(H,56,64)(H4,48,49,51)(H,53,61,67);5*(H,6,7)/t31-,36-,37-;;;;;/m0...../s1
Standard InChI Key: VQCZOBZKBAZEJU-OUOHYALTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 931.16 | Molecular Weight (Monoisotopic): 930.5552 | AlogP: -0.49 | #Rotatable Bonds: 23 |
Polar Surface Area: 292.55 | Molecular Species: BASE | HBA: 13 | HBD: 10 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.56 | CX Basic pKa: 11.99 | CX LogP: -3.24 | CX LogD: -8.50 |
Aromatic Rings: 2 | Heavy Atoms: 67 | QED Weighted: 0.04 | Np Likeness Score: -0.56 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):